URIPAN SYRUP; oxybutynin, genitourinary agents .
ACTIVE-INGREDIENT OF URIPAN SYRUP
each bottle 100 gm contains 0.1 gm oxybutyninhydrochloride .
INDICATION OF URIPAN SYRUP
urinary incontinence , urgency and frequency in the unstable bladder , whether due to neurogenic bladder disorders ( detrusor hyperreflexia ) in conditions such as multiple sclerosis and spina bifida , or to idopathic detrusor instability ( motor urge incontinence ) . – children over 5 years of age : in addition to neurogenic bladder disorders , uripan may also be used in nocturnal enuresis in conjunction with non-drug therapy where this alone , or in conjunction with other drug treatment , has failed .
DOSAGE OF URIPAN SYRUP
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
adults : the usual dose is 5 mg two or three times daily . This may increased to a maximum of 5 mg four times daily to obtain a clinical response provided that the side effects are tolerated . – elderly : the elimination half life is increased in the elderly , therefore , a dose of 2.5 mg twice a day , particularly if the patient is frail , is likely to be adequate . this dose may be tilrated upward to 5 mg two times a day to obtain a clinical response provided that the side effects are tolerated . – children ( under 5 years of age ) : no recommended . children ( over 5 years of age ) : neurogenic bladder : the usual dose is 2.5 mg ( approximately half teaspoonful ) twice a day . this dose may be tilrated upwards to 5 mg ( approximately one teaspoonful ) two or three times a day to obtain a clinical response provided that the side effects are tolerated . nocturnal enuresis : the usual dose is 2.5 mg ( approximately half teaspoonful ) twice a day . this dose may be titrated upwards to 5 mg (approximately one teaspoonful ) two or three times a day to obtained a clinical response provided that the side effects are tolerated . the last dose should be given before bedtime .
OVER-DOSAGE OF URIPAN SYRUP
the symptoms of overdose with oxybutynin progress from an intensification of the usual side effects of CNS disturbances ( from restlessness and and excitement to psychotic behavior ) , circulation changes ( flushing , fall in blood pressure, circulatory failure etc ) , respiratory failure , paralysis and coma measures to be taken are : 1 ) immediate gastric lavage 2 ) physostigmine by slow intravenous injection . adults : 0.5 to 2.0 mg of physostigmine by slow intravenous administration . repeat after 5 minutes , if necessary up to a maximum total dose of 5 mg . – children : 30 micrograms / kg of physostigmine by slow intravenous administration . repeat after 5 minutes , if necessary up to a maximum total dose of 2 mg . fever should be treated symtomatically with tepid sponging or ice packs . in pronounced restlessness or excitation , diazepam 10 mg may be given by intravenous injection , tachycardia may be treated by intravenous injection of propranolol and urinary retention can be managed by catheterisation . in the event of progression of the curare – like effect to the paralysis of the respiratory muscles mechanical ventilation will be required .
CONTRA-INDICATION OF URIPAN SYRUP
hypersensitivity to oxybutynin or any component. Myasthenia gravis . Narrow-angle glaucoma or shallow anterior chamber . Gastrointestinal obstructive disorders including paralytic ileus , intestinal atony . Patients with toxic megacolon . Patients with severe ulcerative colitis . patients with bladder outflow obstruction where urinary relention may be precipitated .
STORAGE OF URIPAN SYRUP
store at temperature not exceeding 30 ° C .
PACK OF URIPAN SYRUP
carton box containing 1 glass bottle of 120 gm + inner leaflet .
URIPAN SYRUP MANUFACTURED BY
ADWIA Co. S.A.E. Tenth of Ramadan City Egypt.